VRTX Vertex Pharmaceuticals Incorporated

225.48
-12.47  -5%
Previous Close 237.95
Open 232.12
Price To Book 9.61
Market Cap 58,459,882,350
Shares 259,268,593
Volume 1,482,254
Short Ratio
Av. Daily Volume 1,966,776
Stock charts supplied by TradingView

NewsSee all news

  1. Vertex Confirms Supply Chain Continuity and Business Outlook for Its Cystic Fibrosis Medicines and Provides Initial Update on Development Programs

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today confirmed its 2020 business outlook and the continuity of the company's supply chain for its approved cystic fibrosis (CF) medicines and provided an update on its

  2. The Vertex Foundation Donates $500,000 to Partners HealthCare to Support COVID-19 Outbreak Response

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that the Vertex Foundation, a nonprofit charitable foundation, is making a $500,000 gift to Partners HealthCare, a Boston-based nonprofit hospital and

  3. Vertex Confirms Supply Chain Continuity and 2020 Business Outlook

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today confirmed that the global coronavirus outbreak has not had any impact on the company's supply chain or its 2020 business outlook. "The challenges facing the

  4. Vertex Announces Cancellation of its March 3 Presentation at the Cowen Health Care Conference

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced the cancellation of its planned March 3 presentation and webcast at the Cowen Health Care Conference. Following implementation of a companywide travel

  5. Vertex Announces Availability of Cystic Fibrosis Medicine KALYDECO® (ivacaftor) in New Zealand

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that KALYDECO® (ivacaftor) will be available to eligible patients with cystic fibrosis (CF) in New Zealand from March 1. Clinicians are able to apply for

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 positive data released November 27, 2018. 14% improvement in ppFEV1 cf placebo.
VX-659 in combination with tezacaftor and ivacaftor
Cystic fibrosis (CF) who have one F508del mutation and one minimal function mutation (F508del/Min)
Label expanded to now include all patients over 6 years old - June 21, 2019.
Tezacaftor / ivacaftor
Cystic fibrosis - Two Copies of the F508del Mutation
Phase 2 data released July 18, 2017. ppFEV1 of 12.0 percentage points.
VX-440 in combination with tezacaftor and ivacaftor
Cystic fibrosis who have one F508del mutation and one minimal function mutation and patients with two copies of the F508del mutation
Approved December 29, 2014.
KALYDECO
Cystic fibrosis (CF) ages 6 and older who have the R117H mutation
Phase 2 primary endpoint met - January 25, 2017.
VX-150
Osteoarthritis
CRL issued February 5, 2016.
KALYDECO (ivacaftor)
Cystic fibrosis (CF) ages 2 and older who have one of 23 residual function mutations.
Approved July 2, 2015.
Lumacaftor and ivacaftor
Cystic fibrosis (CF) ages 12 and older who have two copies of the F508del mutation
Approved March 17, 2015.
KALYDECO (ivacaftor)
Children ages 2 to 5 with cystic fibrosis who have the G551D or one of the eight additional gating mutations
NDA filing due 1Q 2018.
ORKAMBI
Two Copies of the F508del Mutation - children ages 2 to 5
Phase 3 data released October 25, 2017 - primary endpoint not met.
Tezacaftor (VX-661) / ivacaftor
Cystic fibrosis - one copy of the F508del mutation and a second mutation that results in a gating mutation
Phase 3 trial terminated August 2016
VX-661
Cystic fibrosis - one copy of the F508del mutation and a second mutation that results in minimal CFTR Function
Approved September 28, 2016.
ORKAMBI
Cystic fibrosis (CF) ages 6-11 who have F508del mutation
Phase 2 data released July 18, 2017. ppFEV1 of 9.7 percentage points.
VX-152 in combination with tezacaftor and ivacaftor
Cystic fibrosis who have one F508del mutation and one minimal function mutation and patients with two copies of the F508del mutation
Phase 2 data released December 18, 2018. Primary endpoint met.
VX-150
Neuropathic pain
Phase 3 positive data released November 27, 2018. 10% improvement in ppFEV1 cf placebo.
VX-659 in combination with tezacaftor and ivacaftor
Cystic Fibrosis Who Have Two Copies of the F508del Mutation
FDA Approval announced October 21, 2019.
VX-445 in combination with tezacaftor and ivacaftor
Cystic fibrosis (CF) who have one copy of the F508del mutation and one minimal function mutation and patients with two copies of the F508del mutation
Phase 1/2 further data due in 2020.
CTX001
Sickle cell disease
Phase 1/2 further data due in 2020.
CTX001
Beta-thalassemia
FDA Approval announced August 7, 2018.
Ivacaftor
Cystic fibrosis (CF) ages 2 to 5.
Approval announced August 15, 2018.
Lumacaftor and ivacaftor
Cystic fibrosis (CF) ages 1-2.
FDA Approval announced April 30, 2019.
Ivacaftor
Cystic Fibrosis (6-12 mths)
sNDA filing due late 2018.
Tezacaftor and ivacaftor
Cystic Fibrosis (Age 6-11)
Phase 2 monotherapy trial initiated 2Q 2019.
VX-561
Cystic fibrosis who have a gating mutation
Phase 2 combo trial initiated May 2019.
VX-561 and VX-121
Cystic Fibrosis
Phase 2 data due in 2020.
VX-814
alpha-1 antitrypsin (AAT) deficiency
Phase 2 trial to be initiated in 2020.
VX-147
Focal segmental glomerulosclerosis (FSGS)
Phase 1 trial ongoing.
VX-864
Alpha-1 antitrypsin (AAT) deficiency
Phase 3 data and sNDA filing due 2020.
Elexacaftor, tezacaftor and ivacaftor
Children ages 6 to 11 years who have two F508del mutations and one F508del mutation and one minimal function mutation

Latest News

  1. Vertex Confirms Supply Chain Continuity and Business Outlook for Its Cystic Fibrosis Medicines and Provides Initial Update on Development Programs

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today confirmed its 2020 business outlook and the continuity of the company's supply chain for its approved cystic fibrosis (CF) medicines and provided an update on its

  2. The Vertex Foundation Donates $500,000 to Partners HealthCare to Support COVID-19 Outbreak Response

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that the Vertex Foundation, a nonprofit charitable foundation, is making a $500,000 gift to Partners HealthCare, a Boston-based nonprofit hospital and

  3. Vertex Confirms Supply Chain Continuity and 2020 Business Outlook

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today confirmed that the global coronavirus outbreak has not had any impact on the company's supply chain or its 2020 business outlook. "The challenges facing the

  4. Vertex Announces Cancellation of its March 3 Presentation at the Cowen Health Care Conference

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced the cancellation of its planned March 3 presentation and webcast at the Cowen Health Care Conference. Following implementation of a companywide travel

  5. Vertex Announces Availability of Cystic Fibrosis Medicine KALYDECO® (ivacaftor) in New Zealand

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that KALYDECO® (ivacaftor) will be available to eligible patients with cystic fibrosis (CF) in New Zealand from March 1. Clinicians are able to apply for

  6. Vertex to Present at the Cowen Health Care Conference on March 3

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that management will present at the Cowen Health Care Conference on Tuesday, March 3, 2020 at 10:00 a.m. ET. The audio portion of management's

  7. Vertex Reports Full-Year and Fourth-Quarter 2019 Financial Results

    - Full-year 2019 total GAAP product revenues of $4.16 billion - - Full-year 2019 total non-GAAP product revenues of $4.00 billion, a 32% increase compared to the full-year 2018 - - Company provides full-year 2020

  8. Vertex to Announce Full-Year and Fourth-Quarter 2019 Financial Results on January 30

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report its full-year and fourth-quarter 2019 financial results on Thursday, January 30, 2020 after the financial markets close. The company will host a conference

  9. Vertex to Present at the J.P. Morgan Healthcare Conference on January 13

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that management will present at the J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 2:30 p.m. ET (11:30 a.m. PT). The audio portion of

  10. Oncorus Appoints Mary Kay Fenton to its Board of Directors

    -- Announces additional $10 million in Series B financing, bringing total round gross proceeds to $89.6 million -- Oncorus, Inc., a viral immunotherapies company focused on driving innovation to transform outcomes for

  11. Vertex and Republic of Ireland Expand Long-Term Cystic Fibrosis Medicines Reimbursement Agreement to Include Triple Combination Therapy for All Eligible Patients Ages 12 and Over Once Licensed

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today confirmed that, following recent collaborative discussions, it has negotiated an agreement with the Health Service Executive (HSE) in the Republic of Ireland to

  12. Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) in Infants With Cystic Fibrosis Ages 6 Months to Less Than 12 Months With Certain Mutations in the CFTR Gene

    - Ivacaftor is the first and only approved medicine in Europe to treat the underlying cause of cystic fibrosis in children this young - Vertex Pharmaceuticals (Europe) Limited today announced that the European

  13. French Authorities Approve National Reimbursement of ORKAMBI (lumacaftor/ivacaftor) for Eligible People Ages Two and Older With Cystic Fibrosis

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that the French Authorities (Comité économique des produits de santé, or CEPS) have approved national reimbursement of ORKAMBI® (lumacaftor/ivacaftor)

  14. CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies

    -Two patients treated with CTX001 successfully engrafted and demonstrated an initial safety profile consistent with myeloablative busulfan conditioning and autologous hematopoietic stem cell transplant- -Beta

  15. Vertex and Molecular Templates Establish Collaboration to Discover and Develop Novel Targeted Conditioning Regimens to Enhance Hematopoietic Stem Cell Transplants

    -Molecular Templates to receive $38 million upfront payment, including equity investment, with potential for additional milestone and royalty payments on future sales- BOSTON and AUSTIN, Texas, Nov. 18, 2019 (GLOBE

  16. Vertex Confirms Wales Offer Accepted for Access to All Licensed Cystic Fibrosis Medicines

    -Eligible patients in Wales will soon have access to ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor), expanded access to KALYDECO® (ivacaftor) under same terms as NHS England agreement- Vertex

  17. Vertex Confirms Northern Ireland Offer Accepted for Cystic Fibrosis Medicines

    -Eligible patients in Northern Ireland will soon have access to ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor), expanded access to KALYDECO® (ivacaftor) under same terms as NHS England agreement-

  18. Vertex to Present at the Credit Suisse Healthcare Conference on November 12

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that management will present at the Credit Suisse Healthcare Conference on Tuesday, November 12, 2019 at 1:30 p.m. ET. Management's remarks will be

  19. Phase 3 Results from Two Studies of TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) Triple Combination Treatment for Cystic Fibrosis Concurrently Published in The New England Journal of Medicine and The Lancet

    - Both studies met primary and all key secondary endpoints demonstrating significant improvements in lung function and other measures of the disease - - Results of both studies to be presented today at the 33rd Annual

  20. Vertex Announces European Medicines Agency Marketing Authorization Application Validation for VX-445 (Elexacaftor), Tezacaftor and Ivacaftor Triple Combination Treatment in Cystic Fibrosis

    - Application supported by positive results from two global Phase 3 studies in people with cystic fibrosis ages 12 and older with one F508del mutation and one minimal function mutation and in people with two F508del

  21. Vertex Reports Third-Quarter 2019 Financial Results

    - Product revenues of $950 million, a 21% increase compared to Q3 2018 - - Continued progression of pipeline of investigational medicines in multiple diseases - Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today

  22. Vertex Announces Agreement with NHS England for Access to All Licensed Cystic Fibrosis Medicines

    -Eligible patients in England will have access to ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor), expanded access to KALYDECO® (ivacaftor)- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today

  23. Vertex to Announce Third-Quarter 2019 Financial Results on October 30

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report its third quarter 2019 financial results on Wednesday, October 30, 2019 after the financial markets close. The company will host a conference call and

  24. FDA Approves TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older Who Have at Least One F508del Mutation

    - For the first time, approximately 6,000 patients with one minimal function mutation and one F508del mutation have a medicine to treat the underlying cause of their disease– -12,000 people with one or two F508del

  25. Spanish Government Approves National Reimbursement of ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor) in Combination With KALYDECO® (ivacaftor)

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that the Spanish Government has approved terms for the national reimbursement of ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor) in

  26. Vertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Patients Ages 12 and Older, and ORKAMBI® (lumacaftor/ivacaftor) in Children Ages 2 to 5, With Certain CFTR Mutations in Australia

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) is reimbursed in Australia for people with cystic fibrosis (CF) ages 12 years and older who are

  27. Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Eligible Infants with Cystic Fibrosis as Early as 6 Months of Age

    - If approved, ivacaftor will be the first and only medicine to treat the underlying cause of cystic fibrosis for children this young - Vertex Pharmaceuticals (Europe) Limited today announces that the European

  28. Vertex Appoints Carmen Bozic, M.D., as New Chief Medical Officer and Nia Tatsis, Ph.D., as New Chief Regulatory Officer

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Carmen Bozic, M.D., has been appointed as the company's Executive Vice President, Global Medicines Development and Medical Affairs. Dr. Bozic will

  29. Vertex and Ribometrix Establish Strategic Collaboration to Discover and Develop RNA-Targeted Small Molecule Therapeutics

    -Partnership will leverage Ribometrix's discovery platform for up to three therapeutic programs- -Ribometrix to receive $20 million in upfront payment and Vertex equity investment; potential for additional milestones

  30. Vertex Announces New Access Agreement with Scottish Government for ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor)

    Eligible patients in Scotland will immediately have access to ORKAMBI (lumacaftor/ivacaftor) and SYMKEVI (tezacaftor/ivacaftor) in combination with ivacaftor Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today

  31. Vertex to Present at the Morgan Stanley Global Healthcare Conference on September 11

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that management will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2019 at 12:15 p.m. ET. The audio portion of

  32. Vertex to Acquire Semma Therapeutics With a Goal of Developing Curative Cell-Based Treatments for Type 1 Diabetes

    -Semma's unique investigational approach combines robust production process of pancreatic islet cells with proprietary delivery system to restore insulin secretion in type 1 diabetes patients- -Semma to be acquired